Artelo Biosciences' $16.3 Billion Glaucoma Expansion Highlights Multi-Platform Pipeline Strength

Artelo Biosciences is expanding into the $16.3 billion glaucoma market with a fully funded clinical study. The company has three clinical-stage programs in oncology support, neuropathic pain, and CNS disorders, with a lead compound also being explored in ophthalmology. Artelo has attracted academic partners, received regulatory guidance, and drawn partnership inquiries from global pharmaceutical companies. The company's lean structure and successful advancement of three separate compounds through human clinical trials support its growth potential.